News Releases
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
VANCOUVER, British Columbia – March 4, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma to Participate at Upcoming Investor Conferences
VANCOUVER, British Columbia – Feb. 18, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia – Feb. 12, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
VANCOUVER, British Columbia – Feb. 09, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
VANCOUVER, British Columbia – Jan. 20, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Begins Trading on Nasdaq Today
VANCOUVER, British Columbia – Jan. 08, 2026 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Announces Filing of Form F-10 Registration Statement with the SEC under MJDS
VANCOUVER, British Columbia – Dec. 17, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Announces Proposed Amendment to Warrants
VANCOUVER, British Columbia – Dec. 12, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durableand wide-ranging upper and lower-body improvements
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
VANCOUVER, British Columbia – Nov. 19, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
VANCOUVER, British Columbia – Nov. 18, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity